A Quest to End AIDS

Research partnerships with Ontario Universities develop...

a preventative HIV vaccine, based on genetically modified viruses, changing the world’s understanding of how to approach HIV and AIDS treatment. 

Since the beginning of the HIV epidemic, almost 78 million people have been infected with the virus and about 39 million have died.  The virus was characterized in 1983 and there have been many trials to develop vaccines, but none has been successful to date.  Yet there is hope. Western University’s Chil-Yong Kang, working with Sumagen Canada Inc, has developed the first and only preventative HIV vaccine based on a genetically modified killed whole virus, which is currently in Phase II Clinical Trials.

It is the only Canadian-developed HIV vaccine in clinical trials, and one of only a few in the world.

HIV vaccine produces no adverse effects in trials